v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04359810 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : May 19, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : May 19, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
mo2130@cumc.columbia.edu |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-04-24 |
Recruitment status
Last imported at : May 19, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : Nov. 7, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Nov. 14, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
inclusion criteria: - willing and able to provide written informed consent prior to performing study procedures or have a legally authorized representative available to do so. - age ≥18 years - evidence of sars-cov-2 infection by pcr test of naso-/oro-pharyngeal swab or tracheal aspirate sample within 14 days of randomization - peripheral capillary oxygen saturation (spo2) ≤ 94% on room air or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation at screening - evidence of infiltrates on chest radiography - females of childbearing age and males, must be willing to practice an effective contraceptive method or remain abstinent during the study period. |
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
participation in another clinical trial of anti-viral agent(s) for covid-19 receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration [1] mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days severe multi-organ failure history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria known immunoglobulin a (iga) deficiency females who are pregnant use of remdesivir as treatment for covid-19 is permitted. |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : May 19, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Max O'Donnell |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Countries
Last imported at : Nov. 7, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Brazil;United States |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Severe disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
6: Severe disease at enrollment |
Total sample size
Last imported at : May 19, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
223 |
primary outcome
Last imported at : Nov. 7, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Day 28 severity outcome |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 322, "treatment_name": "Convalescent plasma", "treatment_type": "Convalescent plasma", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |